Dianthus Therapeutics, Inc. /DE/ Operating Lease, Liability, Noncurrent
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Operating Lease, Liability, Noncurrent of $913.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability, Noncurrent $913.00K.
- 2026-03-31: Operating Lease, Liability, Noncurrent $965.00K.
- 2025-12-31: Operating Lease, Liability, Noncurrent $1.02M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $1.07M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $913.00K 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $965.00K 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.02M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.07M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.12M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.17M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.17M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $30.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $97.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $168.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $257.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $438.00K 10-K · filed 2024-03-21 | $26.14M 10-K · filed 2023-03-23 |
| 2022-09-30 | $27.18M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $28.19M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $29.10M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |